Video: Dr. Casella reviews vitamin B3 for glaucoma management

Article

A world-first clinical trial led by the Centre for Eye Research Australia shows vitamin B3 (nicotinamide) could play an important role in protecting against nerve cell damage that leads to blindness in glaucoma patients. Chief Optometric Editor, Ben Casella, OD, FAAO, says it's exciting news, but more research needs to be done.

Related: Glaucoma & ocular surface preservation: Key factors for ODs to consider

Recent Videos
EyeCon Co-chair Oluwatosin U. Smith, MD talks passion for research and education in ophthalmology
Lorraine Provencher, MD, presenting slides
Nazlee Zebardast, MD, MSc, overviews her ARVO 2024 presentations on glaucoma and polygenic risk scores
Michael Chaglasian, OD, details success of new OCT device at the ARVO 2024 meeting
Melissa Tawa, OD, FAAO
Deborah Ristvedt, DO, details CIME 2024 presentation on glaucoma management
Shan Lin, MD, speaks on Glaucoma 360 presentation in an interview with Ophthalmology Times
Bonnie An Henderson, MD, highlights key takeaways of the 2024 EnVision Summit, including diversity and family inclusion
© 2024 MJH Life Sciences

All rights reserved.